Swiss Chemicals Stock News

Partners Group recently reported its Assets under Management as of 31 December 2025 and confirmed it will host a 2025 Business Update and 2026 Outlook presentation on 14 January 2026, offering fresh detail on its operations and plans. This combination of an AuM disclosure and upcoming outlook briefing gives investors a clearer window into how the firm is positioning its private-markets platform for the next phase of growth and product development. We’ll now explore how the latest AuM...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Today is shaping up negative for Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders, with the analysts delivering...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Forbo Holding fair value estimate is CHF1,327 Current share...

If you have been wondering whether Alcon is quietly turning into a bargain or just a value trap, you are not alone. This article is going to unpack what the current share price is really implying. The stock has slipped about 1.6% over the last week but is still up 2.5% over the past month, while longer term returns of about 2.1% over three years and 13.8% over five years show a much slower burn than many investors hoped for after a year to date drop of 17.2% and a 16.1% slide over the last...

Roche Holding (SWX:ROG) just picked up an FDA win for expanded use of its PATHWAY anti HER2 and VENTANA HER2 tests, widening the pool of metastatic breast cancer patients eligible for ENHERTU based on more granular HER2 profiling. See our latest analysis for Roche Holding. That FDA nod slots into a busy few weeks for Roche, with new oncology and diagnostics data out of major conferences and fresh European approvals helping underpin a roughly 24.6% 3 month share price return and 29.8% 1 year...

Key Insights Significant control over Comet Holding by retail investors implies that the general public has more power...

Givaudan (SWX:GIVN) is back in focus after its shares slid more than 5% when management stopped short of reaffirming full year sales growth guidance and flagged tougher market conditions alongside softer than expected Q4 growth. See our latest analysis for Givaudan. That cautious tone has landed on a stock that was already under pressure, with a 1 month share price return of minus 9.63% and a 1 year total shareholder return of minus 22.53%, even though the 3 year total shareholder return is...

As the pan-European STOXX Europe 600 Index experienced a slight decline, with mixed performances across major stock indexes such as Germany's DAX and France's CAC 40, investors are closely watching the European Central Bank's potential policy moves amid resilient economic indicators. In this environment of cautious optimism and potential rate hikes, dividend stocks can offer a reliable income stream for investors seeking stability and growth in their portfolios.

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...

The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...

Holcim (SWX:HOLN) is back in the spotlight after landing yet another spot on CDP’s A List for climate and water, while also being tagged a top pick by Deutsche Bank. See our latest analysis for Holcim. Against that backdrop, Holcim’s 9.73% 90 day share price return and 70.34% one year total shareholder return suggest momentum is building again, even after a weaker year to date share price. If Holcim’s circular construction push has you thinking about the broader opportunity set, this could be...

Swiss Prime Site (SWX:SPSN) has just wrapped up its CHF 300 million growth push by buying a fully let, modern office property in Zurich West, locking in a 4% net yield with SIX Group as tenant. See our latest analysis for Swiss Prime Site. This latest Zurich West deal lands as the share price sits at CHF 117.9 and builds on solid momentum, with an 18.8% year to date share price return and a strong 3 year total shareholder return of 68.5%. This suggests investors are steadily rewarding the...

The analysts covering Montana Aerospace AG ( VTX:AERO ) delivered a dose of negativity to shareholders today, by making...

Key Insights TX Group's significant insider ownership suggests inherent interests in company's expansion 51% of the...

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

Italian competition authorities have opened an antitrust investigation into Swatch Group and Japan’s Citizen Watch over allegedly imposing online retail prices and retaliating against distributors who offered discounts, potentially breaching European Union rules. The probe highlights growing regulatory attention on how global watchmakers manage online distribution and pricing power across their authorized retail networks. We will now examine how this antitrust scrutiny of Swatch Group’s...

In recent days, Swiss lawmakers proposed a compromise to ease some of the post–Credit Suisse capital requirements for UBS, including allowing the bank to count Additional Tier 1 instruments toward foreign-subsidiary capital needs and introducing a cap on investment banking risk. This regulatory shift could materially influence how UBS allocates capital between safety buffers, growth initiatives, and shareholder distributions, with longer-term consequences for its global competitiveness and...

Swiss Re (SWX:SREN) has provided medium-term guidance, targeting net income above USD 4.4 billion in 2025 and around USD 4.5 billion in 2026, giving investors clearer earnings visibility. See our latest analysis for Swiss Re. The guidance lands after a busy stretch for Swiss Re, with leadership changes and shifting sentiment around reinsurance risk. The stock’s 30 day share price return of minus 14.33 percent contrasts with its robust five year total shareholder return of 112.19 percent,...

Alcon stock performance in focus Alcon (SWX:ALC) has slipped over the past week and month, extending a rough year for shareholders, even as revenue and net income keep growing. This raises questions about whether the current valuation is overly cautious. See our latest analysis for Alcon. With the share price down 18.2 percent year to date at about CHF 62.50, the recent weekly pullback suggests momentum is still fading even though multi year total shareholder returns remain modestly positive...

Recent Share Performance and Context Kuehne + Nagel International (SWX:KNIN) has quietly staged a rebound, with the stock up about 9% over the past month even as its year to date and 1 year returns remain negative. See our latest analysis for Kuehne + Nagel International. That rebound sits against a tougher backdrop, with the share price still showing a negative year to date return and a 1 year total shareholder return of around minus 12 percent. This suggests sentiment may be stabilising...

Key Insights Significant control over Givaudan by retail investors implies that the general public has more power to...